How Do Donor-recipient CMV Serostatus and Post-hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients?
Background: This study evaluated CMV serostatus in donors and recipients of hematopoietic stem cell transplantation (HSCT) and its effects on CMV reactivation of patients and all aspects of CMV on HSCT outcomes.
Subjects and Methods: Seven hundred and five adult acute leukemia patients (AML=408 and AML=297) who had undergone HSCT were included in this retrospective study. We categorized donor-recipient pairs in three risk groups: positive donors (D+) were studied as high-risk group, including either R+ or R-(n=485), R-D- as low-risk group (n=32) and R+D- as intermediate group (n=15).
Results: There was no statistically difference in CMV reactivation among these risk groups (P=0.14).CMV infection rate was lower in R+D+ than R+D-(p=0.050). Multivariate analysis showed that patients developing CMV infection had lower overall survival (p=0.04, HR: 1.43, CI=1.00- 2.05) and higher non- relapse mortality (P=0.01, HR: 1.62, CI=1.11-2.38). Relapse rate did not change in CMV reactivated patients (P=0.94).
Conclusion:The results of the study indicated that asCMV reactivation occurred more in R+D- patients compared to R+D+ ones, and was associated with inferior OS and higher NRM it could be suggested that in contrast to general belief, if the recipient is seropositive ,seropositive donor is preferred to a seronegative one.
Lönnqvist B, Ringdèn O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. Br J Haematol. 1986; 63(4):671–679.
Behrendt CE, Rosenthal J, BolotinE,et al. Donor and recipient CMV sero-status and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant. 2009; 15(1):54–60.
Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011; 118(5):1402–1412.
Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol. 2006; 76(5):414–419.
Remberger M, Ringdén O. Survival after bone-marrow transplantation. Lancet. 2002; 359(9309):888.
Ljungman P, Brand R, EinseleH,et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003; 102(13):4255–4260.
Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001; 98(7):2043–2051.
Erard V, Guthrie KA, Riddell S,et al. Impact of HLA A2 and cytomegalovirus sero-status on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2006; 91(10):1377–1383.
GreenM,Leisenring W, Hu Xie,etal.CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.Blood. 2013; 122(7): 1316–1324.
Takenaka K, Nishida T, Asano-Mori Y,etal.Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015; 21(11):2008-16.
Inagaki J, Noguchi M, Kurauchi K, et al. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia. Biol Blood Marrow Transplant. 2016;22 (2):300-6
Foley B,Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119(11):2665-2674.
Kekik C, Besisik SK, SeyhunY,et al. Relationship between HLA tissue type, CMV infection, and acute graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: single-center experience. Transplant Proc. 2009; 41(9):3859-62.
Jacobsen N, Andersen H K, Skinhøj, P., et al. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scand J Haematol. 1986 May;36(5):499-506.
Ljungman P, Brand R, HoekJ,et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59(4):473-81.
Thomas E, Blume K, Forman SJ,et al KM. Graft-versus-host-disease. In: Thomas E, Blume K, Forman SJ, editors. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999. p. 515-526.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.J Am Stat Assoc. 1958; 53:457-481.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; (50):163-170.
Cox DR. Regression models and life tables (with discussion).JR Stat Soc B. 1972; (34):187-220.
Gray RJ. A class of κ-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; (16): 1141–1154.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;(94): 496–509.
R Core Team (2015). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.
Jaskula E, Bochenska J, KocwinE,et al. CMV Sero-status of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients. Bone Marrow Res. 2012;2012:375075.
George B, Pati N,Gilroy N,et al.Pre-transplant cytomegalovirus (cmv) sero-status remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.transpl infect dis. 2010;12(4):322-9
Green M, Leisenring WM, XieHu, et al.CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.Blood. 2013; 122(7): 1316–1324.
Schmidt-hieberM, LabopinM, BeelenD,etal.CMVsero-status still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the acute leukemia working party of ebmt. Blood. 2013;122(19):3359-64
|Issue||Vol 11, No 3 (2017)|
|CMV serostatus Hematopoietic stem cell transplantation Outcome CMV infection Acute leukemia|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|